FMP

FMP

Enter

LYEL - Lyell Immunopharma, Inc.

Profile of Lyell Immunopharma, Inc.(LYEL), Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for

About

ceo

Dr. Lynn Seely M.D., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.lyell.com

exchange

NASDAQ

Description

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

CIK

0001806952

ISIN

US55083R1041

CUSIP

55083R104

Address

201 Haskins Way

Phone

650 695 0677

Country

US

Employee

224

IPO Date

Jun 17, 2021

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep